Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition
10.3904/kjm.2021.96.3.160
- Author:
Hye-Kyung JUNG
1
;
Seung Joo KANG
;
Yong Chan LEE
;
Hyo-Joon YANG
;
Seon-Young PARK
;
Cheol Min SHIN
;
Sung Eun KIM
;
Hyun Chul LIM
;
Jie-Hyun KIM
;
Su Youn NAM
;
Woon Geon SHIN
;
Jae Myung PARK
;
Il Ju CHOI
;
Jae Gyu KIM
;
Miyoung CHOI
;
Author Information
1. Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
- Publication Type:15
- From:Korean Journal of Medicine
2021;96(3):160-189
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases worldwide. Although its incidence is gradually decreasing, about half of the world's population still get infected. H. pylori infection is responsible for substantial gastrointestinal morbidity worldwide. It is the most common cause of gastric and duodenal ulcers as well as gastric cancer. Since the revision of the H. pylori Clinical Practice Guidelines in 2013, the eradication rate of H. pylori has gradually decreased with the use of classical triple therapy, wherein amoxicillin, clarithromycin, and proton pump inhibitors are administered, for 7 days. According to a nationwide randomized controlled study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was due to increased antimicrobial resistance induced by the use of antibiotics, especially clarithromycin. The update of clinical practice guideline for treatment of H. pylori was developed based on evidence-based medicine by conducting a meta-analysis. The draft recommendations were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines are designed to provide patients, nurses, medical school students, policymakers, and clinicians with clinical evidence to guide primary care and treatment of H. pylori infection. These may differ from current medical insurance standards and will be revised further, if necessary, based on research-based evidence.
